ATA2271 – VJRegenMed

Remaining barriers in commercializing advanced therapies

Simon Ng — Mon, 29 Nov 2021 11:36:57 +0000

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, addresses issues relating to the commercialization of cell and gene therapies. Major challenges remain in terms of logistics and delivery. Off-the-shelf allogeneic therapies can be given to patients quicker than autologous therapies, as in the case of tabelecleucel, a novel CAR-T cell therapy which can be delivered to patients in three days. He additionally highlights reimbursement issues for these one-off treatments. This interview took place at Meeting on the Mesa 2021.

Remaining challenges in developing cell therapies for cancer

Simon Ng — Thu, 25 Nov 2021 18:05:21 +0000

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, discusses the current progress in successfully developing cell therapies for liquid and solid tumors. In the field of hematological malignancies, cell therapies need to improve their response rate and durability of remission in patients, whereas in solid tumors, developing treatments that are as effective as ones used for liquid tumors remain a challenge. Improving in vivo persistence of cell therapies is one strategy to develop treatments that are more efficacious against solid tumors, as in the case of ATA2271, an chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin. This interview took place at Meeting on the Mesa 2021.

The current landscape of allogeneic CAR T-cell therapies

Simon Ng — Thu, 25 Nov 2021 18:05:19 +0000

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, provides an overview of allogeneic chimeric antigen receptor (CAR) T-cell therapies in development. He describes ATA3219, a novel anti-CD19 CAR-T cell therapy developed for B-cell malignancies, as well as ATA2271, a mesothelin-targeted CAR-T immunotherapy for solid tumors. Tabelecleucel is an additional CAR-T cell therapy that treats Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) following hematopoietic cell or solid organ transplantation. This interview took place at Meeting on the Mesa 2021.